Jaguar Health, Inc. (JAGX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Jaguar Health, Inc. (JAGX) Healthcare & Pipeline Overview

Jaguar Health, Inc. is a San Francisco-based biotechnology firm specializing in prescription medicines for gastrointestinal distress, particularly chronic diarrhea, across human and animal health. The company markets Mytesi for HIV/AIDS-related diarrhea and is advancing a pipeline of plant-based drug candidates for multiple indications, including cancer therapy-related diarrhea and orphan diseases.

What Is the Investment Thesis for JAGX?

Jaguar Health, Inc. presents an investment thesis centered on its existing commercial product, Mytesi, and a robust pipeline targeting diverse gastrointestinal conditions in both human and animal health. The company's current revenue stream from Mytesi, which addresses noninfectious diarrhea in HIV/AIDS patients, provides a commercial foundation. A significant value driver lies in the broad development program for crofelemer, with multiple potential indications including cancer therapy-related diarrhea, orphan-drug indications for congenital diarrheal disorders and short bowel syndrome, and supportive care for inflammatory bowel diseases and irritable bowel syndrome. These indications represent substantial market opportunities and could significantly expand the company's addressable market. The animal health segment, with Canalevia targeting chemotherapy-induced and exercise-induced diarrhea in dogs, offers further diversification. While the company currently operates with a profit margin of -115.4%, indicating a focus on R&D and market penetration, the gross margin of 85.1% suggests strong pricing power for its commercialized product. Successful clinical development and regulatory approvals for its pipeline candidates, particularly those with orphan-drug status, could serve as key growth catalysts, potentially transforming the company's financial profile by late 2020s.

Based on FMP financials and quantitative analysis

JAGX Key Highlights

Gross Margin of 85.1% indicates strong profitability on products sold, reflecting effective cost management relative to revenue from Mytesi.

• Profit Margin of -115.4% highlights significant ongoing investments in research and development and commercialization efforts, typical for a biotechnology company with an expanding pipeline.
• Beta of 0.03 suggests very low volatility relative to the overall market, indicating a potentially stable stock price movement.
• Headquartered in San Francisco, US, a prominent hub for biotechnology innovation and talent.
• Operates with 49 employees, indicating a focused and specialized team managing both commercial operations and an extensive drug development pipeline.

Who Are JAGX's Competitors?

JAGX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are JAGX's Key Strengths?

Commercial-stage product (Mytesi) generating revenue with a high gross margin (85.1%).

• Extensive and diversified pipeline of drug candidates (crofelemer, lechlemer, Canalevia) targeting multiple human and animal GI indications.
• Focus on plant-based medicines, offering a potentially differentiated therapeutic approach.
• Pursuit of orphan-drug designations for severe, rare conditions, which can offer market exclusivity and premium pricing.
• Experienced leadership team with a history in pharmaceutical development.

What Are JAGX's Weaknesses?

Significant negative profit margin (-115.4%), indicating substantial operating losses and reliance on external financing.

• Small market capitalization ($0.00B), potentially limiting access to capital and increasing stock volatility.
• Reliance on a single commercial product (Mytesi) for current revenue, making the company vulnerable to market shifts or competition for this product.
• Long and costly clinical development and regulatory approval processes for pipeline candidates, with no guarantee of success.
• Limited employee base (49 employees) for managing a broad pipeline and commercial operations.

What Could Drive JAGX Stock Higher?

JAGX catalyst: Announcement of positive clinical trial results for crofelemer in cancer therapy-related diarrhea, potentially leading to regulatory submission.

• Granting of orphan-drug designation or accelerated approval pathway for crofelemer for congenital diarrheal disorders or short bowel syndrome with intestinal failure.
• Progress in the clinical development of lechlemer for cholera, including initiation or completion of key clinical phases.
• Regulatory submission or approval for Canalevia in the animal health market for chemotherapy-induced or exercise-induced diarrhea in dogs.
• Strategic partnerships or licensing agreements for pipeline assets to accelerate development or expand market access.

What Are the Key Risks for JAGX?

Financial-distress signal — its Altman Z-Score of -20.06 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Failure of any of Jaguar Health's pipeline candidates, including crofelemer for its various indications, lechlemer, or Canalevia, to meet primary endpoints in clinical trials.
• Significant negative profit margin (-115.4%) indicates the company's continued reliance on external financing, posing a risk of dilution or inability to fund operations.
• Regulatory hurdles or delays in obtaining marketing approvals from health authorities for new drug candidates, impacting commercialization timelines and costs.
• Intense competition within the biotechnology and pharmaceutical sectors, potentially limiting market share or pricing power for existing and future products.
• Market acceptance and reimbursement challenges for new products, even if approved, due to existing treatment options or payer policies.

What Are the Growth Opportunities for JAGX?

• Growth opportunity 1: Expansion of Crofelemer for Cancer Therapy-Related Diarrhea (CTD). The market for managing side effects of cancer treatment, including CTD, represents a significant unmet need. As cancer therapies become more potent and varied, the incidence of CTD is expected to rise. Crofelemer's mechanism of action could offer a differentiated treatment option, potentially improving patient quality of life and adherence to life-saving cancer treatments. The global oncology supportive care market is projected to grow, offering a substantial addressable market for this indication, with potential for regulatory filings and commercialization in the late 2020s.
• Growth opportunity 2: Orphan-Drug Indications for Crofelemer. Jaguar Health is pursuing orphan-drug designations for crofelemer for congenital diarrheal disorders (CDD) and short bowel syndrome with intestinal failure (SBS-IF). These rare conditions affect small patient populations but often come with significant medical needs and premium pricing potential due to limited treatment options and regulatory incentives. Securing orphan-drug status could accelerate development and provide market exclusivity, creating a high-value, specialized market segment for the company with potential regulatory milestones in the mid-to-late 2020s.
• Growth opportunity 3: Crofelemer for Inflammatory Bowel Diseases (IBD), Irritable Bowel Syndrome (IBS), and Idiopathic Diarrhea. These conditions represent large patient populations globally, with millions suffering from chronic diarrhea. While existing treatments are available, there remains a need for effective and well-tolerated options. Crofelemer's anti-secretory properties could offer supportive care for diarrhea relief in IBD and a targeted treatment for diarrhea-predominant IBS and idiopathic functional diarrhea. The sheer size of these markets offers substantial commercial potential, with clinical development and potential market entry extending into the late 2020s and early 2030s.
• Growth opportunity 4: Development of Lechlemer for Cholera. Cholera remains a significant public health concern in many parts of the world, particularly in developing regions. Lechlemer, as a second-generation anti-secretory agent, could provide an important therapeutic option for this acute and potentially fatal diarrheal disease. Addressing global health challenges can attract funding, partnerships, and humanitarian initiatives, alongside commercial opportunities in endemic areas. Successful development and approval of lechlemer could position Jaguar Health as a key player in infectious disease management, with potential for clinical progress in the mid-to-late 2020s.
• Growth opportunity 5: Canalevia for Animal Health. The animal health market, particularly for companion animals, is experiencing consistent growth, with owners increasingly seeking advanced medical treatments for their pets. Canalevia, an oral plant-based drug candidate for chemotherapy-induced diarrhea and exercise-induced diarrhea in dogs, taps into this trend. As veterinary oncology advances, the need for supportive care like managing chemotherapy side effects grows. This segment offers a complementary revenue stream and market diversification, leveraging the company's expertise in gastrointestinal health. Commercialization and market penetration for Canalevia could expand throughout the late 2020s.

What Threats Does JAGX Face?

• Failure of pipeline drug candidates in clinical trials or inability to secure regulatory approvals.
• Intense competition from larger pharmaceutical companies with greater financial resources and established market presence in GI disorders.
• Market acceptance and reimbursement challenges for new products, particularly in specialized or orphan indications.
• Potential for generic competition or new treatments impacting Mytesi's market share.
• Ongoing need for significant capital to fund research, development, and commercialization, with potential for dilution through equity financing.

What Are JAGX's Competitive Advantages?

• Specialized focus on gastrointestinal distress, particularly chronic diarrhea, allowing for deep expertise and targeted product development.
• Proprietary plant-based drug candidates, such as crofelemer and lechlemer, derived from sustainable sources, offering a unique pharmacological profile.
• Existing commercial product, Mytesi, provides a market presence and revenue stream, supporting ongoing pipeline development.
• Pursuit of orphan-drug designations for specific indications, which can provide market exclusivity and expedited regulatory pathways.
• Diversified approach across both human and animal health segments, mitigating risk and expanding addressable markets.

What Does JAGX Do?

Jaguar Health, Inc., established in 2013 and headquartered in San Francisco, California, is a commercial-stage pharmaceuticals company dedicated to developing and commercializing prescription medicines for individuals and animals suffering from gastrointestinal distress, with a specific focus on chronic and debilitating diarrhea. The company strategically operates through two distinct segments: Human Health and Animal Health, allowing for a diversified approach to addressing significant unmet medical needs. In its Human Health segment, Jaguar Health successfully markets Mytesi (crofelemer) for the symptomatic relief of noninfectious diarrhea in adults living with HIV/AIDS who are on antiretroviral therapy. This product represents a key revenue stream and foundational asset for the company. Beyond Mytesi, Jaguar Health is actively developing crofelemer for a range of additional indications, demonstrating its commitment to expanding the therapeutic utility of its lead compound. These potential follow-on indications include the management of cancer therapy-related diarrhea, which affects a substantial patient population undergoing various oncology treatments. Furthermore, the company is pursuing orphan-drug designations for crofelemer to address symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders (CDD) and for adult and pediatric patients with short bowel syndrome with intestinal failure (SBS-IF), targeting rare and severe conditions. Other human health pipeline initiatives for crofelemer encompass supportive care for diarrhea relief in inflammatory bowel diseases (IBD), diarrhea-predominant irritable bowel syndrome (IBS-D), and idiopathic/functional diarrhea, collectively addressing a broad spectrum of chronic diarrheal conditions. In addition to crofelemer, Jaguar Health is developing lechlemer, a second-generation anti-secretory agent specifically designed for the treatment of cholera, a severe diarrheal disease. The Animal Health segment focuses on Canalevia, an oral plant-based drug candidate. Canalevia is being developed to treat chemotherapy-induced diarrhea in dogs, a common and distressing side effect of cancer treatment in pets, and exercise-induced diarrhea in dogs, aiming to improve the quality of life for companion animals.

What Products and Services Does JAGX Offer?

• Develops and commercializes prescription medicines for gastrointestinal distress in humans and animals.
• Markets Mytesi (crofelemer) for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
• Conducts clinical trials for crofelemer for multiple follow-on indications, including cancer therapy-related diarrhea.
• Pursues orphan-drug indications for crofelemer to treat diarrhea in infants/children with congenital diarrheal disorders and patients with short bowel syndrome.
• Develops crofelemer for supportive care in inflammatory bowel diseases, irritable bowel syndrome, and idiopathic/functional diarrhea.
• Researches lechlemer, a second-generation anti-secretory agent, for the treatment of cholera.
• Develops Canalevia, an oral plant-based drug candidate, for chemotherapy-induced and exercise-induced diarrhea in dogs.
• Operates through two distinct segments: Human Health and Animal Health.

How Does JAGX Make Money?

• Generates revenue from the commercial sale of Mytesi (crofelemer) to treat noninfectious diarrhea in HIV/AIDS patients.
• Invests in research and development to advance a pipeline of drug candidates, primarily crofelemer and lechlemer, for various human gastrointestinal conditions.
• Develops and seeks regulatory approval for Canalevia, a plant-based drug for animal health applications, aiming for future commercial sales in the veterinary market.
• Potentially seeks partnerships or licensing agreements for pipeline assets to fund development or expand market reach.
• Leverages plant-based compounds to create novel therapeutic options for both human and animal health.

What Industry Does JAGX Operate In?

Jaguar Health, Inc. operates within the dynamic and innovation-driven biotechnology industry, specifically focusing on gastrointestinal health. This sector is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for effective treatments addressing chronic conditions. The market for gastrointestinal disorders is substantial, driven by increasing prevalence of conditions like IBS, IBD, and diarrhea associated with other therapies (e.g., cancer treatment, HIV/AIDS). Jaguar Health's strategy of developing plant-based prescription medicines positions it uniquely within this landscape. While numerous pharmaceutical companies compete in the broader GI space with various drug classes, Jaguar Health's focus on anti-secretory mechanisms and specific niche indications, such as noninfectious diarrhea in HIV/AIDS and orphan diarrheal disorders, allows it to carve out a distinct market position. The company's animal health segment also taps into the growing pet care pharmaceutical market, which is experiencing consistent growth due to increased pet ownership and willingness to spend on animal health.

Who Are JAGX's Key Customers?

• Adults with HIV/AIDS experiencing noninfectious diarrhea while on antiretroviral therapy.
• Oncology patients suffering from cancer therapy-related diarrhea.
• Infants and children with congenital diarrheal disorders (CDD) and adult/pediatric patients with short bowel syndrome with intestinal failure (SBS-IF).
• Patients with inflammatory bowel diseases (IBD), diarrhea-predominant irritable bowel syndrome (IBS-D), and idiopathic/functional diarrhea.
• Veterinarians and pet owners seeking treatments for chemotherapy-induced diarrhea and exercise-induced diarrhea in dogs.
• Global health organizations and governments in regions affected by cholera outbreaks.

The most recent 12 insider filings for Jaguar Health, Inc. break down as 0 sales and 12 purchases. On net that is roughly 155K shares acquired (about $112K) — insiders putting money in tends to read as conviction.

Jaguar Health, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 0.7% below estimates on average.

Jaguar Health, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -20.06 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

Return on assets is -91.1%, showing how much profit it generates from its asset base. A current ratio of 0.50 means current liabilities exceed short-term assets, a liquidity point worth watching.

Jaguar Health, Inc. (JAGX) Valuation Context

Analyst price targets span from $3.21 to $3.21, with a consensus of $3.21. At the current price of $0.32, that implies approximately 906% upside potential. Relative to its peer group, JAGX's quantitative score of 20/100 is below the peer average of 88/100.

JAGX Revenue & Earnings Trend

In Q2 FY2026, JAGX generated $1.2M in top-line revenue, marking a sequential decrease of 94.0%. The company recorded a net loss of $12.7M, with diluted EPS of $-15.67. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, JAGX averaged $-83.62 in diluted EPS.

Company Profile

Jaguar Health, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Francisco, US. The company is led by CEO Lisa A. Conte. JAGX has traded publicly since 2015.

JAGX Financials

JAGX Latest News

JAGX Analyst Consensus

JAGX MoonshotScore

Latest Jaguar Health, Inc. Analysis

JAGX Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources